## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of all claims in the application.

### Listing of Claims

1 - 87. (Cancelled)

88. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution ~~at position 239~~selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to ~~said~~ its parent ~~Fc polypeptide~~ antibody or immunoadhesin, and wherein numbering is according to the EU index.

89. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein numbering is according to the EU index.

90. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution ~~at position 239~~selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to ~~said~~ its parent ~~Fc polypeptide~~ antibody or immunoadhesin, wherein numbering is according to the EU index.

91. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F~~,~~ 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the

group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein numbering is according to the EU index.

92. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of of 239D, 239E, 239N, 239Q, 239F~~,~~ 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at position 332, wherein numbering is according to the EU index.

93. (Cancelled) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239 and at position 332, wherein numbering is according to the EU index.

94. (Currently Amended) An antibody or immunoadhesin according to claim 92 ~~or 93~~ wherein said substitution at position 332 is selected from the group consisting of I332D, I332E, I332N, I332Q, I322T, I332H, I332Y, and I332A.

95. (Previously Presented) An antibody or immunoadhesin according to claim 92 comprising the amino acid substitutions 239D and 332E.

96. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution ~~at position 239~~selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H,

299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

97. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, ~~239N,~~ 239Q, ~~239F,~~ and 239T, ~~239H and 239Y~~, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

98. (Currently Amended) An antibody or immunoadhesin according to claim 88 or 89 which is selected from the group consisting of 239E/332E, 239Q/332E, 239E/265G, 239E/265N, 239E/265Q, 239D/332D, 239D/332E, 239D/332N, 239D/332Q, 239E/332D, 239E/332N, 239E/332Q, ~~239N/332D, 239N/332E, 239N/332N, 239N/332Q,~~ 239Q/332D, 239Q/332N, 239Q/332Q, 239E/264I/332E, 239Q/264I/332E, 239E/264I/330Y/332E, 239E/264I/298A/330Y/332E, 239D/297D/332E, 239E/297D/332E, 239D/265V/297D/332E, 239D/265I/297D/332E, 239D/265L/297D/332E, 239D/265F/297D/332E, 239D/265Y/297D/332E, 239D/265H/297D/332E, 239D/265T/297D/332E, ~~239N/330Y/332E,~~ 239D/330L/332E, ~~239N/330L/332E,~~ 264I/298A/332E, 239D/298A/332E, ~~239N/298A/332E,~~ 239D/264I/332E, 239D/264I/298A/332E, 332E/239D/298A, 239D/330Y/332E and 239D/264I/330L/332E.

99. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E.

100. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E/330Y.

101. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E/330L.

102. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E/298A.

103. (Currently Amended) An antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, ~~239N,~~ 239Q, ~~239F,~~ and 239T, ~~239H and 239Y~~, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to ~~said~~ its parent ~~polypeptide~~ antibody or immunoadhesin, wherein numbering is according to the EU index.

104. (Previously Presented) An antibody or immunoadhesin according to claim 103 wherein said FcγR is FcγRIIIa.

105. (Previously Presented) An antibody or immunoadhesin according to claim 104 wherein said FcγRIIIa is a V158 or F158 allotype of FcγRIIIa.

106. (Currently Amended) An antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 wherein said substitution is 239D.

107. (Currently Amended) An antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 wherein said substitution is 239E.

108. (Currently Amended) An antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 wherein said antibody or immunoadhesin is an antibody.

109. (Currently Amended) An antibody according to claim 108 wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody ~~and an antibody fragment~~.

110. (Withdrawn - Currently Amended) An antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 wherein said antibody or immunoadhesin further comprises an engineered glycoform.

111. (Currently Amended) An antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 wherein said antibody or immunoadhesin has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

112. (Currently Amended) A composition comprising the antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 further comprising a pharmaceutically acceptable carrier.

113. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution ~~at position 239~~ selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to ~~said~~ its parent ~~Fc polypeptide~~ antibody or immunoadhesin, and wherein numbering is according to the EU index.

114. (Withdrawn – Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~,

said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N~~239N,~~ 239Q, ~~239F,~~ and 239T, ~~239H and 239Y~~, wherein numbering is according to the EU index.

115. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution ~~at position 239~~ selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to ~~said~~ its parent ~~Fc polypeptide~~ antibody or immunoadhesin, wherein numbering is according to the EU index.

116. (Withdrawn – Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or ~~immunoadhesin of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein numbering is according to the EU index.

117. (Withdrawn – Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at position 332, wherein numbering is according to the EU index.

118. (Cancelled) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239 and at position 332, wherein numbering is according to the EU index.

119. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 117, ~~and 118~~ wherein said substitution at position 332 is selected from the group consisting of I332D, I332E, I332N, I332Q, I322T, I332H, I332Y, and I332A.

120. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 119 comprising the amino acid substitutions 239D and 332E.

121. (Withdrawn – Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

122. (Withdrawn – Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

123. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim ~~113 or 114~~ 122, which is selected from the group consisting of 239E/332E, 239Q/332E, 239E/265G, 239E/265N, 239E/265Q, 239D/332D, 239D/332E, 239D/332N, 239D/332Q, 239E/332D, 239E/332N, 239E/332Q, ~~239N/332D, 239N/332E, 239N/332N, 239N/332Q,~~ 239Q/332D, 239Q/332N, 239Q/332Q, 239E/264I/332E, 239Q/264I/332E, 239E/264I/330Y/332E, 239E/264I/298A/330Y/332E, 239D/297D/332E, 239E/297D/332E, 239D/265V/297D/332E, 239D/265I/297D/332E, 239D/265L/297D/332E, 239D/265F/297D/332E, 239D/265Y/297D/332E, 239D/265H/297D/332E, 239D/265T/297D/332E, 239N/330Y/332E, 239D/330L/332E, ~~239N/330L/332E, 264I/298A/332E,~~ 239D/298A/332E, ~~239N/298A/332E,~~ 239D/264I/332E, 239D/264I/298A/332E, 332E/239D/298A, 239D/330Y/332E and 239D/264I/330L/332E.

124. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E.

125. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E/330Y.

126. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E/330L.

127. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E/298A.

128. (Withdrawn – Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin ~~of a parent Fc polypeptide~~, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F 239T, 239H and 239Y, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to ~~said~~ its parent ~~polypeptide~~ antibody or immunoadhesin, wherein numbering is according to the EU index.

129. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 103 wherein said FcγR is FcγRIIIa.

130. (Withdrawn - Previously Presented) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 104 wherein said FcγRIIIa is a V158 or F158 allotype of FcγRIIIa.

131. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to any of claims 113-11~~8~~7, ~~121~~-122 and 124-127 wherein said antibody or immunoadhesin is an antibody.

132. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody according to claim 131 wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody ~~and an antibody fragment~~.

133. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to any of claims 113-1187, ~~121~~-122 and 124-127 wherein said antibody or immunoadhesin further comprises an engineered glycoform.

134. (Withdrawn - Currently Amended) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to any of claims 88-~~93~~92 and 96-97 wherein said antibody or immunoadhesin has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNF~~alpha~~-α, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

135. (New) An antibody or immunoadhesin comprising a 239D amino acid substitution, wherein said numbering is according to the EU index.

136. (New) An antibody or immunoadhesin comprising a 239E amino acid substitution, wherein said numbering is according to the EU index.

137. (New) An antibody or immunoadhesin according to claim 135 or 136 wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to its parent antibody or immunoadhesin.

138. (New and withdrawn) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claims 135 or 136, wherein said antibody or immunoadhesin is an antibody.